Michael Schreinlechner

Smartphone-based screening for atrial fibrillation: a pragmatic randomized clinical trial

Konstantinos D. Rizas, Luisa Freyer, Nikolay Sappler et al. · Nature Medicine · 2022 · 104 citations

Electrophysiological Evaluation, Cardiovascular Disease, Remote Patient Monitoring +8

Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial

Axel Bauer, Michael Schreinlechner, Nikolay Sappler et al. · The Lancet Respiratory Medicine · 2021 · 101 citations · Full text

Open-label Trial, Hypertension, Cardiovascular Disease +9

Expression of a recombinant full-length LRP1B receptor in human non-small cell lung cancer cells confirms the postulated growth-suppressing function of this large LDL receptor family member

Arno Beer, Christoph Zenzmaier, Michael Schreinlechner et al. · Oncotarget · 2016 · 46 citations · Full text

Smartwatch-derived heart rate variability: a head-to-head comparison with the gold standard in cardiovascular disease

Fabian Theurl, Michael Schreinlechner, Nikolay Sappler et al. · European Heart Journal - Digital Health · 2023 · 42 citations · Full text

Telemedical cardiac risk assessment by implantable cardiac monitors in patients after myocardial infarction with autonomic dysfunction (SMART-MI-DZHK9): a prospective investigator-initiated, randomised, multicentre, open-label, diagnostic trial

Axel Bauer, Nikolay Sappler, Lukas von Stülpnagel et al. · The Lancet Digital Health · 2022 · 27 citations · Full text